PFS was defined as the time from the start of erlotinib administration to disease progression (or death for patients without disease progression who died from any cause). Efficacy analyses were stratified by age (<75 years vs. 75–84 years and ≥85 years or ≥75 years), previous treatment (gefitinib vs. no gefitinib), and ECOG PS (PS 0–2 vs. PS 3–4). The safety population comprised all patients who received erlotinib

and had a case report form data available. The efficacy population comprised all patients included in the safety population, except those where erlotinib therapy was prescribed off-label (first line) at the time of this study, or where a patient’s therapeutic history was unknown. Median PFS was estimated AZD4547 concentration using Kaplan–Meier methodology. Patients without data for the duration of the observation period or from the time of treatment initiation were excluded from analyses of PFS. Statistical analyses were performed using Statistical Analysis Software version 9.1. The log-rank test was used to generate P values. Of 10,708 patients registered, the full safety population of the POLARSTAR study comprised 9909 patients. Of these, 9907 were eligible for safety assessment in this analysis. A total of 7848 (79.2%) Anti-cancer Compound Library cost patients were aged <75 years, 1911 (19.3%) were aged 75–84 years, and 148 (1.5%) were aged ≥85 years. A total of 9651

patients were eligible for efficacy assessment and, of these, 7701 (79.8%) were aged <75 years, 1815 (18.8%) were aged 75–84 years, and 135 (1.4%) were aged ≥85 years. Baseline characteristics were well balanced between the age groups (Table 1). In regard to the average daily dose of erlotinib, the mean value for each patient group was slightly lower in patients aged ≥85 years (130 mg) compared with patients aged <75 years

(140 mg) or 75–84 years (135 mg); however, the median value was equal (150 mg) between the age groups. Median duration of erlotinib administration was 55 days, 57 days, and 50.5 days for patients aged <75 years, 75–84 years, and ≥85 years, respectively (Supplementary Table SI). The numbers of patients who required erlotinib dose interruptions and/or reductions were comparable (Supplementary Table SII). Supplementary Table S1.   Duration of exposure to erlotinib. The incidence of ILD (all Edoxaban grades) was 4.2% in patients aged <75 years, 5.1% in patients aged 75–84 years, and 3.4% in patients aged ≥85 years (Table 2). The mortality rate due to ILD was 1.5% in patients aged <75 years, 1.7% in patients aged 75–84 years, and 1.4% in patients aged ≥85 years. Nonhematologic toxicities were generally similar between groups (Table 2). Grade 1–4 hematologic toxicities (neutropenia, leukopenia, anemia, and thrombocytopenia) were observed at <1.0% in each group. One patient had grade 5 anemia (<75 year age group) and one patient had grade 5 thrombocytopenia (75–84 year age group).